News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
10,719 Results
Type
Article (249)
Company Profile (13)
Press Release (10457)
Section
Business (2793)
Career Advice (4)
Deals (362)
Drug Development (1235)
FDA (215)
Job Trends (393)
News (4381)
Policy (272)
Tag
2027 Genetown Standard (2)
Academia (36)
Accelerated approval (1)
Allergies (3)
Alliances (585)
ALS (16)
Alzheimer's disease (40)
Antibody-drug conjugate (ADC) (19)
Approvals (230)
Artificial intelligence (13)
ASCO (19)
Autoimmune disease (10)
Automation (1)
Bankruptcy (3)
Belgium (2)
Best Places to Work (370)
BIO (1)
Biologics (5)
Biosimilars (1)
Biotechnology (12)
Bispecific (2)
Bladder cancer (5)
Brain cancer (10)
Breast cancer (62)
Cancer (251)
Cardiovascular disease (4)
Career advice (5)
CAR-T (14)
CDC (1)
CDMO (4)
Cell therapy (42)
Clinical research (1222)
Collaboration (56)
Commercialization (1)
Compensation (69)
Complete response letters (3)
COVID-19 (15)
CRISPR (2)
C-suite (51)
Cystic fibrosis (1)
Data (362)
Depression (4)
Dermatology (2)
Diabetes (7)
Diagnostics (105)
Digital health (1)
Drug discovery (8)
Drug pricing (1)
Duchenne muscular dystrophy (44)
Earnings (1040)
Editorial (1)
ESMO (21)
Events (2595)
Executive appointments (41)
FDA (331)
Friedreich's ataxia (1)
Frontotemporal dementia (7)
Funding (48)
Gene editing (4)
Generative AI (1)
Gene therapy (30)
GLP-1 (16)
Government (42)
Guidances (7)
Healthcare (339)
Hematology (9)
Idiopathic pulmonary fibrosis (1)
IgA nephropathy (2)
Immunology and inflammation (8)
Immuno-oncology (1)
Indications (5)
Infectious disease (21)
Inflammatory bowel disease (7)
Influenza (1)
Intellectual property (12)
IPO (165)
Job creations (22)
Job search strategy (4)
JPM (1)
Kidney cancer (2)
Kidney disease (5)
Labor market (3)
Layoffs (3)
Legal (53)
Licensing (1)
Liver cancer (3)
Lung cancer (25)
Lymphoma (9)
Machine learning (1)
Manufacturing (25)
Marketing (1)
MASH (2)
Medical device (259)
Medtech (281)
Mergers & acquisitions (232)
Metabolic disorders (17)
mRNA (4)
Multiple sclerosis (8)
Netherlands (2)
Neurodegenerative disease (14)
Neuropsychiatric disorders (1)
Neuroscience (97)
NextGen: Class of 2026 (150)
Non-profit (104)
Now hiring (11)
Obesity (6)
Opinion (2)
Ovarian cancer (4)
Pain (18)
Pancreatic cancer (25)
Parkinson's disease (7)
Patents (23)
Patient recruitment (34)
Patient selection (4)
People (1022)
Phase 1 (507)
Phase 2 (551)
Phase 3 (314)
Pipeline (371)
Policy (1)
Postmarket research (33)
Preclinical (235)
Prostate cancer (13)
Psychedelics (1)
Radiopharmaceuticals (31)
Rare diseases (55)
Real estate (97)
Regenerative medicine (1)
Regulatory (331)
Research institute (33)
Rett syndrome (1)
RNA editing (1)
Series A (12)
Series B (5)
Service/supplier (1)
Sickle cell disease (13)
Spinal muscular atrophy (1)
Sponsored (1)
Startups (36)
Substance use disorders (1)
Tariffs (2)
The Weekly (2)
Vaccines (10)
Weight loss (1)
Wet AMD (1)
Women's health (6)
Worklife (1)
Date
Today (8)
Last 7 days (25)
Last 30 days (83)
Last 365 days (809)
2026 (690)
2025 (828)
2024 (953)
2023 (931)
2022 (927)
2021 (946)
2020 (740)
2019 (693)
2018 (525)
2017 (375)
2016 (389)
2015 (429)
2014 (324)
2013 (234)
2012 (285)
2011 (291)
2010 (262)
Location
Africa (10)
Alabama (1)
Arizona (1)
Arkansas (1)
Asia (249)
Australia (201)
California (284)
Canada (36)
China (26)
Colorado (4)
Connecticut (24)
Delaware (5)
Europe (1065)
Florida (98)
Georgia (4)
Idaho (1)
Illinois (55)
Indiana (43)
Iowa (1)
Japan (10)
Kentucky (2)
Maryland (22)
Massachusetts (450)
Michigan (1)
Minnesota (4)
Missouri (1)
New Hampshire (2)
New Jersey (52)
New York (59)
North Carolina (71)
North Dakota (1)
Northern California (97)
Ohio (5)
Oregon (1)
Pennsylvania (59)
Puerto Rico (1)
Rhode Island (2)
South America (10)
Southern California (164)
Tennessee (3)
Texas (569)
United States (1779)
Utah (6)
Virginia (2)
Washington D.C. (3)
Washington State (14)
Wisconsin (1)
10,719 Results for "Dyne_tx".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 22, 2026
October 23, 2026
·
2 min read
Press Releases
Dyne Therapeutics to Participate in Upcoming September 2026 Investor Conferences
September 2, 2026
·
1 min read
Press Releases
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - September 17, 2026
September 17, 2026
·
2 min read
Press Releases
Dyne Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights
November 5, 2026
·
9 min read
Press Releases
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - August 20, 2026
August 20, 2026
·
2 min read
Press Releases
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 24, 2026
July 27, 2026
·
2 min read
Press Releases
Dyne Therapeutics to Present Preclinical Data for Multiple Development Candidates for Duchenne Muscular Dystrophy (DMD) at 27th Annual NMSG Scientific Meeting
September 3, 2026
·
5 min read
Press Releases
Dyne Therapeutics to Participate in Upcoming Investor Conferences - May 13, 2026
May 13, 2026
·
1 min read
Press Releases
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 18, 2026
June 19, 2026
·
2 min read
Press Releases
Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)
September 29, 2026
·
12 min read
1 of 1,072
Next
